XBiotech, a biopharmaceutical company developing first-in-class antibody therapies, located in Austin, Texas, has revealed its breakthrough True Human™ therapeutic antibody.
XBiotech claims that this therapeutic antibody is able to neutralize a pro-inflammatory molecule known as interleukin-6 (IL-6), which has proven to be very beneficial for patients afflicted with autoimmune diseases or cancer. Although several other antibody agents that specifically work against IL-6 have begun clinical trials and even actual approved distribution, XBiotech is confident that their product can bring something new and improved into the market.
Replicated and produced from actual human immune responses, these True Human™ antibodies are expected to be the safest option among antibody treatment choices, with minimal risk for adverse reactions. The company is currently focused on coming up with an effective and efficient manufacturing process so as to be ready to begin clinical studies in the next year.
Dr. Sushma Shivaswamy, the company’s Director of Research, is quoted in saying, “”We are very gratified to identify and launch a new True Human™ antibody from our discovery engine. Identifying these antibodies from the human population is the culmination of a coordinated and technically challenging program. Seeing these antibodies ultimately used in the clinic is particularly satisfying. We hope many patients will benefit from this natural human therapeutic.”
To learn more about XBiotech’s breakthrough biopharmaceutical products, visit http://www.xbiotech.com/.